Search Results - Aibin Liang

Refine Results
  1. 1

    Comparison of efficacy and adverse effects of CD19/20 CART versus CD19 single-target CART in R/R DLBCL: a single-center retrospective study by Bin Xue, Bin Xue, Yifan Liu, Bing Li, Yan Lu, Lili Zhou, Shiguang Ye, Huina Lu, Xiu Luo, Aibin Liang, Aibin Liang, Ping Li

    Published in Frontiers in Immunology (2025-05-01)
    Get full text
    Article


  2. 2

    Combining CAR-T therapy with radiotherapy or not in refractory/relapsed diffuse large B-cell lymphoma: A comparative study by Yun Yang, Bichun Xu, Hong Zhu, Weikai Sun, Aibin Liang, Judong Luo

    Get full text
    Article


  3. 3

    Upregulation of CD19 by low‐dose chidamide promotes CAR T cells functionality in B-cell non-Hodgkin lymphoma by Ying Ni, Qun Zhang, Xiaochen Tang, Xiuchun Li, Shiguang Ye, Yan Lu, Aibin Liang, Ping Li

    Published in Discover Oncology (2025-01-01)
    Get full text
    Article


  4. 4

    Phosphorylation‐Dependent Stabilization of Collaborator of ARF (CARF) Suppresses Lymphoma Cell Proliferation by Li Qu, Zhuang Wei, Shuting Zhou, Xiaofan Zhang, Wenjun Zhang, Aibin Liang, Zhe Wang, Hongwei Xue

    Published in Advanced Science (2025-09-01)
    Get full text
    Article


  5. 5

    Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials by Yang Xu, Ping Li, Yang Liu, Dijia Xin, Wen Lei, Aibin Liang, Weidong Han, Wenbin Qian

    Published in Cancer Communications (2022-06-01)
    Get full text
    Article


  6. 6

    Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy by Ying Ni, Lixia Gao, Yan Lu, Shiguang Ye, Lili Zhou, Wenbin Qian, Aibin Liang, Ping Li

    Published in Frontiers in Immunology (2022-08-01)
    Get full text
    Article


  7. 7

    Challenges and optimal strategies of CAR T therapy for hematological malignancies by Yajing Zhang, Yang Xu, Xiuyong Dang, Zeyu Zhu, Wenbin Qian, Aibin Liang, Weidong Han, Peifang Wei

    Published in Chinese Medical Journal (2023-02-01)
    Get full text
    Article


  8. 8

    CD70‐targeting CAR‐T cells have potential activity against CD19‐negative B‐cell Lymphoma by Wenhai Deng, Panpan Chen, Wen Lei, Yang Xu, Nengwen Xu, Jeffrey J. Pu, Aibin Liang, Wenbin Qian

    Published in Cancer Communications (2021-09-01)
    Get full text
    Article


  9. 9

    Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen rec... by Xiuyong Dang, Ping Li, Aijun Shen, Yan Lu, Zeyu Zhu, Min Zhang, Wenbin Qian, Aibin Liang, Wenjun Zhang

    Published in Cancer Medicine (2024-03-01)
    Get full text
    Article


  10. 10

    Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with BTK inhibitors by Jingjing Zhu, Xinyu Zhu, Fengyang Xie, Yi Ding, Huina Lu, Yan Dong, Ping Li, Jianfei Fu, Aibin Liang, Yu Zeng, Bing Xiu

    Published in Pathology and Oncology Research (2023-04-01)
    Get full text
    Article


  11. 11

    Outcomes and risk factors of SARS‐CoV‐2 omicron variant in B‐cell lymphoma patients following CD19 targeted CAR‐T therapy by Xibin Xiao, Panpan Chen, Yadi Zhong, Xiu Luo, Yao Liu, Ying Lu, Xueli Jin, Wenbin Qian, Weidong Han, Aibin Liang, Hui Liu

    Published in Cancer Medicine (2023-11-01)
    Get full text
    Article


  12. 12

    LILRB4 regulates multiple myeloma development through STAT3-PFKFB1 pathway by Li Xie, Chiqi Chen, Tinghua Zhang, Wenqian Yang, Denghao Zheng, Liyuan Cao, Jin Yuan, Yilu Xu, Yaping Zhang, Ligen Liu, Aibin Liang, Zhuo Yu, Junke Zheng

    Published in Cell Death and Disease (2024-07-01)
    Get full text
    Article


  13. 13

    An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk by Bin Xue, Yifan Liu, Min Zhang, Gangfeng Xiao, Xiu Luo, Lili Zhou, Shiguang Ye, Yan Lu, Wenbin Qian, Li Wang, Ping Li, Aibin Liang, Sihan Zhou, Xiuyuan Hao

    Published in Chinese Medical Journal (2025-01-01)
    Get full text
    Article


  14. 14

    Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation by Cheng Zhang, Xiaoqi Wang, Hai Yi, Yi Wang, Zhiling Yan, Jian Zhou, Ting Yang, Aibin Liang, Zhen Wang, Yingying Ma, Qin Wen, Lei Gao, Li Gao, Peiyan Kong, Xu Tan, Erlie Jiang, Xi Zhang

    Published in Journal of Hematology & Oncology (2024-10-01)
    Get full text
    Article


  15. 15

    A broadly neutralizing antibody recognizes a unique epitope with a signature motif common across coronaviruses by Lei Yan, Fulian Wang, Michelle Hill, Juliane Brun, Ze Liang, Xinyu Shi, Liangminghui Zhang, Xiuxiu He, Yu Li, Qianping Huang, Xuxue Dong, Huanzhen Liu, Yi Zhang, Lili Liu, Raymond A. Dwek, Nicole Zitzmann, Aibin Liang, Guang Yang

    Published in Nature Communications (2025-08-01)
    Get full text
    Article


  16. 16

    Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial by Hui Liu, Hao Jiang, Hongyan Tong, Ruixiang Xia, Linhua Yang, Hongguo Zhao, Jian Ouyang, Hai Bai, Hui Sun, Li Hou, Ming Jiang, Yun Zeng, Zhuogang Liu, Aibin Liang, Yinghua Xie, Kang Yu, Zhimin Zhai, Li Liu, Jinsong Jia, Rong Fu, Zonghong Shao

    Published in Cancer Medicine (2023-07-01)
    Get full text
    Article


  17. 17

    Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia by Ying Wang, Lulu Lv, Yongping Song, Xudong Wei, Hongsheng Zhou, Qifa Liu, Kailin Xu, Dongmei Yan, Cheng Zhang, Shuangyou Liu, Jie Jin, Heng Mei, Ting Niu, Aibin Liang, Runxia Gu, Jienan Ren, Yi Feng, Wei Jin, Yan Zhou, Yiping Deng, Jianxiang Wang

    Published in Blood Advances (2025-02-01)
    Get full text
    Article


  18. 18

    Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma by Huaqing Wang, Jifeng Feng, Yanyan Liu, Zhengzi Qian, Da Gao, Xuehong Ran, Hui Zhou, Lihong Liu, Binghua Wang, Meiyun Fang, Hebing Zhou, Zhenqian Huang, Shi Tao, Zhuowen Chen, Liping Su, Hang Su, Yu Yang, Xiaobao Xie, Huijing Wu, Ping Sun, Guoyu Hu, Aibin Liang, Zhiming Li

    Published in Signal Transduction and Targeted Therapy (2024-04-01)
    Get full text
    Article


  19. 19

    Chinese expert consensus on integrated case management by a multidisciplinary team in CAR-T cell therapy for lymphoma by Sanfang Tu, Ping Li, Heng Mei, Yang Liu, Yongxian Hu, Peng Liu, Dehui Zou, Ting Niu, Kailin Xu, Li Wang, Jianmin Yang, Mingfeng Zhao, Xiaojun Huang, Jianxiang Wang, Yu Hu, Weili Zhao, Depei Wu, Jun Ma, Wenbin Qian, Weidong Han, Yuhua Li, Aibin Liang, Sihan Zhou, Xiuyuan Hao

    Published in Chinese Medical Journal (2025-08-01)
    Get full text
    Article


  20. 20

    The influence of CRS and ICANS on the efficacy of anti-CD19 CAR-T treatment for B-cell acute lymphoblastic leukemia by Yuhan Ma, Hongyuan Zhou, Hongyuan Zhou, Jiaoli Zhang, Qing Zhang, Qing Zhang, Yujie Li, Yujie Li, Ruiyang Xie, Ruiyang Xie, Bingpei Zhang, Bingpei Zhang, Ziyuan Shen, Ping Li, Aibin Liang, Keshu Zhou, Lu Han, Yongxian Hu, Kailin Xu, Kailin Xu, Wei Sang, Wei Sang, Xiangmin Wang, Xiangmin Wang

    Published in Frontiers in Immunology (2024-09-01)
    Get full text
    Article


Search Tools: